DOCSLIB.ORG

Review the Regulation of the ADAMTS4 and ADAMTS5 Aggrecanases in Osteoarthritis: a Review J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Review the Regulation of the ADAMTS4 and ADAMTS5 Aggrecanases in Osteoarthritis: a Review J Review The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review J. Bondeson1, S. Wainwright2, C. Hughes2, B. Caterson2 1Department of Rheumatology, Cardiff ABSTRACT on aggrecan monomers, with the asso- University and 2Connective Tissue Destruction of articular cartilage is a ciated water molecules, is essential for Biology Laboratories, Cardiff School of key feature of a number of arthritides, the ability of articular cartilage to with- Biosciences, Cardiff University, Cardiff, osteoarthritis prominent among them. stand compressive deformation during UK. Aggrecan degradation, caused by joint articulation (1). The chondrocytes Jan Bondeson, MD PhD; increased activity of proteolytic en- synthetize and catabolize ECM mac- Shane Wainwright, PhD; Clare Hughes, PhD; zymes that degrade macromolecules romolecules, which in turn serve to Bruce Caterson PhD. in the cartilage extracellular matrix, maintain the homeostasis of the cel- This work has been supported by the is followed by irreversible collagen lular environment and the cartilage Arthritis Research Campaign (UK), degradation. The degradation of ag- structure. In diseases like rheumatoid grants no. W0596, 13172 and 14570. grecan is mediated by various matrix arthritis (RA) and osteoarthritis (OA), Please address correspondence to: proteinases, mainly the aggrecanases, degradation of ECM macromolecules Prof. Bruce Caterson, Connective Tissue multidomain metalloproteinases be- exceeds their synthesis, resulting in a Biology Laboratories, Cardiff School of longing to the ADAMTS (a disintegrin net decrease in the amount of cartilage Biosciences, Cardiff University, Museum and metalloproteinase with throm- matrix, eventually leading to total or Avenue, Cardiff CF10 3US, UK. bospondin motifs) family. There has partial erosion of the cartilage. The de- E-mail: [email protected] been much interest in the possible role pletion of aggrecan from articular car- Reprints will not be available from the of these aggrecanases, mainly AD- tilage, as evidenced by the release of authors. AMTS4 and ADAMTS5, as therapeutic aggrecan catabolites into the synovial Received on June 25, 2007; accepted in targets in osteoarthritis. There is still fl uid, is an essential early pathophysi- revised form on November 30, 2007. debate which of them is the major ag- ological event in OA (1-2). The aspect Clin Exp Rheumatol 2008; 26: 139-145. grecanase in osteoarthritis, however, most studied has been the proteolysis of © CopyrightCopyright CLINICAL AND as well as major issues concerning the interglobular domain of aggrecan EXPERIMENTAL RHEUMATOLOGY 2007.2007. how they are regulated, with possible with release of the glycosaminoglycan discrepancies between murine models (GAG)-attachment regions, since it ap- Key words: Aggrecanase, and results obtained using human oste- pears to be the most destructive to tissue interleukin-1, matrix metalloproteinase, oarthritis tissue. This review discusses function. NF-kappaB, osteoarthritis, tumour some recent data regarding the regula- It has been debated whether the prote- necrosis factor alpha. tion of ADAMTS4 and ADAMTS5 gene olysis of the interglobular domain of expression in osteoarthritis, with em- aggrecan is mediated by matrix met- phasis on the role of proinfl ammatory alloproteases (MMPs) or by aggreca- cytokines in driving these enzymes, and nases. The aggrecanases are members of the transcription factor NFκB inin of the family of disintegrin and metal- mediating their expression. loproteases with thrombospondin mo- tifs (ADAMTS) that were fi rst char- Introduction acterised for their ability to cleave the Cartilage consists of a relatively small Glu373-Ala374 bond in the interglobular amount of chondrocytes, embedded in domain of aggrecan (1). These enzymes abundant extracellular matrix (ECM) are regulated at multiple levels through that contains numerous macromol- control of gene expression, mRNA ecules, major constituents being col- splicing and protein processing, as lagen fi brils and the large aggregating well as regulation of the expression of proteoglycan aggrecan. Aggrecan fi lls various naturally occurring inhibitors the interstices of the collagen meshwork (3). Several ADAMTS aggrecanases by forming large aggregated complexes have been identifi ed, among them ag- interacting with hyaluronan and link grecanase-1 (ADAMTS4) and aggre- proteins. The high negative charge den- canase-2 (ADAMTS5). Recent studies Competing interests: none declared. sity of the glycosaminoglycan chains suggest that one or more aggrecanases 139 REVIEW Regulation of aggrecanases in osteoarthritis / J. Bondeson et al. are responsible for cleavage of the interglobular domain with destructive loss of GAG (4-5). ADAMTS4 and ADAMTS5 are multi-domain metallo- proteases secreted from the cell into the extracellular space as furin active pro- teases. They both consist of a catalytic metalloprotease domain and a series of other ancillary domains that play a role in regulating their activity and substrate specifi city (Fig. 1). For example, AD- AMTS4 activity for the interglobular domain cleavage site is increased when the C-terminal spacer domain is re- moved, and additional C-terminal trun- cation also leads to a preferred substrate specifi city for small leucine-rich prote- oglycans and other proteins (6). Another recent study suggests that blocking ag- grecanase cleavage in the interglobular domain of aggrecan diminished aggre- can loss and cartilage erosion in murine models of surgically induced osteoar- Fig. 1. The structure of ADAMTS4, its only known splice variant, and ADAMTS5. thritis and infl ammatory arthritis, and appeared to stimulate repair following AMTS4 gene expression could be up- We used a model to effectively and acute infl ammation (7). regulated through treatment with either specifi cally neutralise the endogenous It has long been debated which of the IL-1β, TNF-α or oncostatin M, there production of these cytokines from ADAMTSs is the main aggrecanase in was little effect on ADAMTS5 in ei- the OA synovial macrophages (18). OA. Due to observations of ADAMTS4 ther human chondrocytes or cultured Cultures were either left untreated, mRNA being inducible through in- human cartilage explants. In contrast, incubated with the p75 TNF soluble terleukin (IL)-1 in chondrocytes, this there was an additive effect of combi- receptor Ig fusion protein etanercept enzyme has attracted a good deal of at- nation treatment with oncostatin M and (Enbrel), incubated with a neutraliz- tention (8-10). But in models of murine either IL-1β or TNF-α in these sys- ing anti-IL-1β antibody, or incubated OA induced by antigen or surgical joint tems, leading to marked induction of with a combination of Enbrel and anti- destabilisation, ADAMTS4-null mice ADAMTS4 gene expression and also IL-1β. There was no effect of either did not show any protective effect on some induction of ADAMTS5 (15). In Enbrel or the neutralizing anti-IL-1β cartilage aggrecan loss compared with OA synovium or cartilage, aggrecanase antibody on ADAMTS5 expression, wild-type mice, whereas there was a activity and expression of ADAMTS4 nor was it at all affected by a combina- marked protective effect in ADAMTS5- and ADAMTS5 is present constitu- tion of these treatments (Fig. 2). Thus null mice (11-13). These studies sug- tively, without any requirement for any ADAMTS5 appears to be constitutive gest that in this model of murine degen- catabolic stimulation (15-16). in OA synovial cells. In contrast, AD- erative arthritis, ADAMTS5 plays a key To investigate the role of TNF-α, and AMTS4 was signifi cantly (p < 0.05) in- role in aggrecan degradation. The sig- IL-1 in driving ADAMTS4 and AD- hibited by Enbrel, and more potently (p nifi cance of this important fi nding for AMTS5 expression in the human OA < 0.01) inhibited by a combination of idiopathic human OA is not yet known. synovium, we used a model of cultures Enbrel and the neutralizing anti-IL-1β of synovial cells from digested OA syn- antibody (Fig. 2). This would indicate The role of proinfl ammatory ovium (17). These cells have the advan- that in the human OA synovium, the cytokines in the regulation of tage of spontaneously producing a vari- upregulation of ADAMTS4 is depend- ADAMTS4 and ADAMTS5 ety of both pro- and anti-infl ammatory ent on TNF-α and IL-1 produced by In models of cultured bovine and cytokines, including TNF-α, IL-1 and the synovial macrophages, whereas the porcine chondrocytes or cartilage IL-10, as well as the major MMPs and level of ADAMTS5 is not changed by explants, ADAMTS4 is induced fol- TIMPs. By means of specifi c neutrali- these cytokines (18). lowing stimulation with IL-1, tumour zation of macrophage-produced TNF-α In contrast to this wealth of data from necrosis factor (TNF)α, oncostatin M and IL-1, it was possible to assess the human, porcine and bovine models or transforming growth factor β, but contribution of these two proinfl amma- indicating that ADAMTS4 mRNA re- ADAMTS5 is not (8-10,14). A recent tory cytokines on ADAMTS4 and AD- sponds to IL-1, there are two recent study (15) indicated that although AD- AMTS5 gene expression. papers indicating that this is not the 140 Regulation of aggrecanases in osteoarthritis / J. Bondeson et al. REVIEW A ADAMTS5 gene expression has also ADAMTS4 become clearer. ADAMTS4, but not ADAMTS5, has several NFκB binding sites on its 5’ fl anking region that are ADAMTS5 conserved between species (22). In bo- Patient 1 vine chondrocytes, ADAMTS4, but not GAPDH ADAMTS5, could be upregulated by IL- 1 stimulation (Fig. 3A). Using a model of transfecting bovine chondrocytes with the 5’ fl anking region of the AD- ADAMTS4 AMTS4 or ADAMTS5 gene luciferase receptor vector, it was observed that the IL-1-induced upregulation of the AD- Patient 2 ADAMTS5 AMTS4 gene involved its 5’ fl anking GAPDH region, whereas the 5’ fl anking region of the ADAMTS5 gene played no part (Fig. 3B). Mutation of any one of the three identifi ed NFκB binding sites re- sulted in the loss of the IL-1 response to the ADAMTS4 gene luciferase reporter B vector (Fig.
Load more

Recommended publications
  • What Are the Roles of Metalloproteinases in Cartilage and Bone Damage? G Murphy, M H Lee
    iv44 Ann Rheum Dis: first published as 10.1136/ard.2005.042465 on 20 October 2005. Downloaded from REPORT What are the roles of metalloproteinases in cartilage and bone damage? G Murphy, M H Lee ............................................................................................................................... Ann Rheum Dis 2005;64:iv44–iv47. doi: 10.1136/ard.2005.042465 enzyme moiety into an upper and a lower subdomain. A A role for metalloproteinases in the pathological destruction common five stranded beta-sheet and two alpha-helices are in diseases such as rheumatoid arthritis and osteoarthritis, always found in the upper subdomain with a further C- and the irreversible nature of the ensuing cartilage and bone terminal helix in the lower subdomain. The catalytic sites of damage, have been the focus of much investigation for the metalloproteinases, especially the MMPs, have been several decades. This has led to the development of broad targeted for the development of low molecular weight spectrum metalloproteinase inhibitors as potential therapeu- synthetic inhibitors with a zinc chelating moiety. Inhibitors tics. More recently it has been appreciated that several able to fully differentiate between individual enzymes have families of zinc dependent proteinases play significant and not been identified thus far, although a reasonable level of varied roles in the biology of the resident cells in these tissues, discrimination is now being achieved in some cases.7 Each orchestrating development, remodelling, and subsequent family does, however, have other unique domains with pathological processes. They also play key roles in the numerous roles, including the determination of physiological activity of inflammatory cells. The task of elucidating the substrate specificity, ECM, or cell surface localisation (fig 1).
    [Show full text]
  • And MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment
    International Journal of Molecular Sciences Review Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment Stephan Niland and Johannes A. Eble * Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, 48149 Münster, Germany; [email protected] * Correspondence: [email protected] Abstract: The tumor microenvironment (TME) has become the focus of interest in cancer research and treatment. It includes the extracellular matrix (ECM) and ECM-modifying enzymes that are secreted by cancer and neighboring cells. The ECM serves both to anchor the tumor cells embedded in it and as a means of communication between the various cellular and non-cellular components of the TME. The cells of the TME modify their surrounding cancer-characteristic ECM. This in turn provides feedback to them via cellular receptors, thereby regulating, together with cytokines and exosomes, differentiation processes as well as tumor progression and spread. Matrix remodeling is accomplished by altering the repertoire of ECM components and by biophysical changes in stiffness and tension caused by ECM-crosslinking and ECM-degrading enzymes, in particular matrix metalloproteinases (MMPs). These can degrade ECM barriers or, by partial proteolysis, release soluble ECM fragments called matrikines, which influence cells inside and outside the TME. This review examines the changes in the ECM of the TME and the interaction between cells and the ECM, with a particular focus on MMPs. Keywords: tumor microenvironment; extracellular matrix; integrins; matrix metalloproteinases; matrikines Citation: Niland, S.; Eble, J.A. Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix 1. Introduction Interactions in the Tumor Microenvironment.
    [Show full text]
  • Human ADAM12 Quantikine ELISA
    Quantikine® ELISA Human ADAM12 Immunoassay Catalog Number DAD120 For the quantitative determination of A Disintegrin And Metalloproteinase domain- containing protein 12 (ADAM12) concentrations in cell culture supernates, serum, plasma, and urine. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 PRECAUTIONS .........................................................................................................................................................................4
    [Show full text]
  • Quantikine® ELISA
    Quantikine® ELISA Human ADAMTS13 Immunoassay Catalog Number DADT130 For the quantitative determination of human A Disintegrin And Metalloproteinase with Thombospondin type 1 motif, 13 (ADAMTS13) concentrations in cell culture supernates, serum, and plasma. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................4 PRECAUTIONS .........................................................................................................................................................................4
    [Show full text]
  • Association of ADAM12 Gene Polymorphisms with Knee Osteoarthritis Susceptibility
    www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2017 Association of ADAM12 gene polymorphisms with knee osteoarthritis susceptibility SUPPLEMENTARY MATERIALS REFERENCES candidate genes for the prevalence and progression of knee osteoarthritis. Arthritis Rheum. 2004;50:2497-2507. 1. Poonpet T, Tammachote R, Tammachote N, Kanitnate S, 11. Kerna I, Kisand K, Laitinen P, Tamm A, Tamm A. Honsawek S. Association between ADAM12 polymorphism Association of metallopeptidase domain 12 (ADAM12) and knee osteoarthritis in Thai population. Knee. gene polymorphisms and ADAM12 protein with the 2016;23:357-361. development of knee osteoarthritis. Osteoarthritis Cartilage. 2. Wang L, Guo L, Tian F, Hao R, Yang T. Analysis of single 2010;18. nucleotide polymorphisms within ADAM12 and risk of 12. Stark K, Straub RH, Blažičková S, Hengstenberg C, knee osteoarthritis in a Chinese Han population. Biomed Rovenský J. Genetics in neuroendocrine immunology: Res Int. 2015;2015:518643. implications for rheumatoid arthritis and osteoarthritis. Ann 3. Lou S, Zhao Z, Qian J, Zhao K, Wang R. Association N Y Acad Sci. 2010;1193. of single nucleotide polymorphisms in ADAM12 gene 13. Limer KL, Tosh K, Bujac SR, McConnell R, Doherty S, with susceptibility to kneeosteoarthritis: a case-control Nyberg F, Zhang W, Doherty M, Muir KR, Maciewicz study in a Chinese Han population. Int J Clin Exp Pathol. RA. Attempt to replicate published genetic associations 2014;7:5154-5159. in a large, well-defined osteoarthritis case-control 4. Kerna I, Kisand K, Tamm AE, Kumm J, Tamm AO. population (the GOAL study). Osteoarthritis Cartilage. Two single-nucleotide polymorphisms in ADAM12 2009;17:782-789. gene are associated with early and late radiographic 14.
    [Show full text]
  • ADAMTS13 and 15 Are Not Regulated by the Full Length and N‑Terminal Domain Forms of TIMP‑1, ‑2, ‑3 and ‑4
    BIOMEDICAL REPORTS 4: 73-78, 2016 ADAMTS13 and 15 are not regulated by the full length and N‑terminal domain forms of TIMP‑1, ‑2, ‑3 and ‑4 CENQI GUO, ANASTASIA TSIGKOU and MENG HUEE LEE Department of Biological Sciences, Xian Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, P.R. China Received June 29, 2015; Accepted July 15, 2015 DOI: 10.3892/br.2015.535 Abstract. A disintegrin and metalloproteinase with thom- proteolysis activities associated with arthritis, morphogenesis, bospondin motifs (ADAMTS) 13 and 15 are secreted zinc angiogenesis and even ovulation [as reviewed previously (1,2)]. proteinases involved in the turnover of von Willebrand factor Also known as the VWF-cleaving protease, ADAMTS13 and cancer suppression. In the present study, ADAMTS13 is noted for its ability in cleaving and reducing the size of the and 15 were subjected to inhibition studies with the full-length ultra-large (UL) form of the VWF. Reduction in ADAMTS13 and N-terminal domain forms of tissue inhibitor of metallo- activity from either hereditary or acquired deficiency causes proteinases (TIMPs)-1 to -4. TIMPs have no ability to inhibit accumulation of UL-VWF multimers, platelet aggregation and the ADAMTS proteinases in the full-length or N-terminal arterial thrombosis that leads to fatal thrombotic thrombocy- domain form. While ADAMTS13 is also not sensitive to the topenic purpura [as reviewed previously (1,3)]. By contrast, hydroxamate inhibitors, batimastat and ilomastat, ADAMTS15 ADAMTS15 is a potential tumor suppressor. Only a limited app can be effectively inhibited by batimastat (Ki 299 nM). In number of in-depth investigations have been carried out on the conclusion, the present results indicate that TIMPs are not the enzyme; however, expression and profiling studies have shown regulators of these two ADAMTS proteinases.
    [Show full text]
  • ADAMTS Proteases in Vascular Biology
    Review MATBIO-1141; No. of pages: 8; 4C: 3, 6 ADAMTS proteases in vascular biology Juan Carlos Rodríguez-Manzaneque 1, Rubén Fernández-Rodríguez 1, Francisco Javier Rodríguez-Baena 1 and M. Luisa Iruela-Arispe 2 1 - GENYO, Centre for Genomics and Oncological Research, Pfizer, Universidad de Granada, Junta de Andalucía, 18016 Granada, Spain 2 - Department of Molecular, Cell, and Developmental Biology, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA Correspondence to Juan Carlos Rodríguez-Manzaneque and M. Luisa Iruela-Arispe: J.C Rodríguez-Manzaneque is to be contacted at: GENYO, 15 PTS Granada - Avda. de la Ilustración 114, Granada 18016, Spain; M.L. Iruela-Arispe, Department of Molecular, Cell and Developmental Biology, UCLA, 615 Charles Young Drive East, Los Angeles, CA 90095, USA. [email protected]; [email protected] http://dx.doi.org/10.1016/j.matbio.2015.02.004 Edited by W.C. Parks and S. Apte Abstract ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) proteases comprise the most recently discovered branch of the extracellular metalloenzymes. Research during the last 15 years, uncovered their association with a variety of physiological and pathological processes including blood coagulation, tissue repair, fertility, arthritis and cancer. Importantly, a frequent feature of ADAMTS enzymes relates to their effects on vascular-related phenomena, including angiogenesis. Their specific roles in vascular biology have been clarified by information on their expression profiles and substrate specificity. Through their catalytic activity, ADAMTS proteases modify rather than degrade extracellular proteins. They predominantly target proteoglycans and glycoproteins abundant in the basement membrane, therefore their broad contributions to the vasculature should not come as a surprise.
    [Show full text]
  • ADAMTS5 Assay, Human
    K-ASSAY KAMIKAMIYAYA BIOMEDICAL COMPANY KAMIYA BIOMEDICAL COMPANY ADAMTS5 Assay For the quantitative determination of human ADAMTS5 mRNA in whole blood, plasma, urine and transplantation tissue Cat. No. KT-697 For research use only, not for use in diagnostic procedures. 1 Revised 9815444 K-ASSAY KAMIKAMIYAYA BIOMEDICAL COMPANY PRODUCT INFORMATION ADAMTS5 Assay Cat. No. KT-697 PRODUCT The K-ASSAY ADAMTS5 Assay is a real time PCR assay for the quantitative determination of human ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5) mRNA in whole blood, plasma, urine and transplantation tissue. For research use only. Not for use in diagnostic procedures. INTRODUCTION Aggrecan is the major proteoglycan in cartilage, and is degraded by ADAMTS5 in arthritic cartilage. Studies in models of cultured bovine and porcine chondrocytes and cartilage explants have reported that ADAMTS5 is not induced by stimulation with IL-1 and TNF α. It has also been shown that ADAMTS5 expression in human synoviocytes is not inhibited by the anti-TNF biologics. PRINCIPLE ADAMTS5 TEST Kit contains specific primers, probes and calibrator DNA for the detection and quantification of human ADAMTS5 mRNA in samples. The test is based on real-time PCR that, in addition to specific forward and reverse oligonucleotide primers, utilizes MGB (minor groove binder) probe to generate a fluorescent signal when specific cDNA is present in samples. Samples, such as whole blood, plasma, urine, and transplantation tissue can be used. COMPONENTS Master Mix: 1 vial, 900 µL ADAMTS5 MGB Probe: 1 vial, 45 µL β-actin MGB Probe: 1 vial, 45 µL ADAMTS5 calibrator DNA: 1 vial, 50 µL β-actin calibrator DNA: 1 vial, 50 µL Each kit contains enough reagents to perform 21 tests.
    [Show full text]
  • P.D187H Mutation Impairs ADAMTS13 Activity and Secretion and Contributes to Thrombotic Thrombocytopenic Purpura in Mice
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Lirias Journal of Thrombosis and Haemostasis, 13: 283–292 DOI: 10.1111/jth.12804 ORIGINAL ARTICLE The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice E. DE COCK,* C. HERMANS,† J. DE RAEYMAECKER,‡ K. DE CEUNYNCK,* B. DE MAEYER,* N. VANDEPUTTE,* A. VANDENBULCKE,* H. DECKMYN,* H. ROTTENSTEINER,§ M. DE MAEYER,‡ S. F. DE MEYER* andK. VANHOORELBEKE* *Laboratory for Thrombosis Research, KU Leuven Kulak, Kortrijk; †Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Brussels; ‡Biochemistry, Molecular and Structural Biology Section, Department of Chemistry, Laboratory of Biomolecular Modeling, KU Leuven, Leuven, Belgium; and §Baxter Innovations GmbH, Vienna, Austria To cite this article: De Cock E, Hermans C, De Raeymaecker J, De Ceunynck K, De Maeyer B, Vandeputte N, Vandenbulcke A, Deckmyn H, Rottensteiner H, De Maeyer M, De Meyer SF, Vanhoorelbeke K. The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice. J Thromb Haemost 2015; 13: 283–92. of ADAMTS13. The homozygous p.D187H mutation Summary. Background: Congenital thrombotic thrombo- down-regulated ADAMTS13 activity in vitro. Impaired cytopenic purpura (TTP) is characterized by mutations in proteolytic activity was linked to unstable Ca2+ binding the ADAMTS13 gene, which either impair protein secre- as visualized using a molecular dynamics simulation. In tion or influence ADAMTS13 (A Disintegrin-like And addition, the p.D187H mutation affects protein secretion Metalloprotease domain with ThromboSpondin type-1 in vitro.InAdamts13–/– mice, the homozygous p.D187H motif, member 13) activity.
    [Show full text]
  • Oncostatin M in Combination with Tumour Necrosis Factor Α Induces a Ann Rheum Dis: First Published As 10.1136/Ard.2004.028191 on 5 May 2005
    ARD Online First, published on May 5, 2005 as 10.1136/ard.2004.028191 Oncostatin M in combination with tumour necrosis factor α induces a Ann Rheum Dis: first published as 10.1136/ard.2004.028191 on 5 May 2005. Downloaded from chondrocyte membrane-associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2. W Hui, HE Barksby, DA Young, TE Cawston, N McKie, AD Rowan Musculoskeletal Research Group, School of Clinical Medical Sciences, University of Newcastle upon Tyne, Newcastle, NE2 4HH, United Kingdom. http://ard.bmj.com/ on September 30, 2021 by guest. Protected copyright. Address reprint requests to Dr. Drew Rowan, Musculoskeletal Research Group, Medical School, University of Newcastle upon Tyne, Newcastle, NE2 4HH, United Kingdom. Tel: 0044 191 222 8821. Fax: 0044 191 222 5455. E-mail: [email protected] KEY WORDS: aggrecanase, ADAMTS, TIMP, chondrocyte, membrane "The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in ARD editions and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://ard.bmjjournals.com/misc/ifora/licenceform.shtml)." 1 Copyright Article author (or their employer) 2005. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. ABSTRACT Objective: We have previously reported that chondrocyte membranes exhibit an aggrecanase Ann Rheum Dis: first published as 10.1136/ard.2004.028191 on 5 May 2005.
    [Show full text]
  • Kartogenin Inhibits Pain Behavior, Chondrocyte Inflammation, And
    www.nature.com/scientificreports OPEN Kartogenin inhibits pain behavior, chondrocyte infammation, and attenuates osteoarthritis Received: 12 January 2018 Accepted: 30 August 2018 progression in mice through Published: xx xx xxxx induction of IL-10 Ji Ye Kwon1, Seung Hoon Lee1, Hyun-Sik Na1, KyungAh Jung2, JeongWon Choi1, Keun Hyung Cho1, Chang-Yong Lee3, Seok Jung Kim4, Sung-Hwan Park1,5, Dong-Yun Shin3 & Mi-La Cho1,2,6 Osteoarthritis (OA) is a major degenerative joint condition that causes articular cartilage destruction. It was recently found that enhancement of chondroclasts and suppression in Treg cell diferentiation are involved in the pathogenesis of OA. Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs). This study aimed to identify whether KGN can enhance severe pain behavior and improve cartilage repair in OA rat model. Induction of OA model was loaded by IA-injection of MIA. In the OA rat model, treatment an intra-articular injection of KGN. Pain levels were evaluated by analyzing PWL and PWT response in animals. Histological analysis and micro-CT images of femurs were used to analyze cartilage destruction. Gene expression was measured by real-time PCR. Immunohistochemistry was analyzed to detect protein expression. KGN injection signifcantly decreased pain severity and joint destruction in the MIA-induced OA model. KGN also increased mRNA levels of the anti-infammatory cytokine IL-10 in OA patients’ chondrocytes stimulated by IL-1β. Decreased chondroclast expression, and increased Treg cell expression. KGN revealed therapeutic activity with the potential to reduce pain and improve cartilage destruction. Thus, KGN could be a therapeutic molecule for OA that inhibits cartilage damage.
    [Show full text]
  • ADAMTS4 Is Upregulated in Colorectal Cancer and Could Be a Useful Prognostic Indicator of Colorectal Cancer
    ADAMTS4 is upregulated in colorectal cancer and could be a useful prognostic indicator of colorectal cancer Xue-Qin Shang1,2 Kui-Liang Liu1 Qian Li1 Yue-Qiong Lao1 Nan-Shan Li1 Jing Wu1 1. Department of Gastroenterology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China. 2. The Second People’s Hospital of Yunnan Province, Oncology Department, Kunming, 650021, China. http://dx.doi.org/10.1590/1806-9282.66.1.42 SUMMARY OBJECTIVE: ADAMTS4 is a member of the ADAMTS4 family, which secretes proteinases. The mechanism of tumor metastasis may be correlated to its promotion of angiogenesis. It was determined whether ADAMTS4 participates in colorectal cancer progression. Methods: The expression in clinical samples and CRC cell lines was investigated. Using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and RT-PCR, the expression of ADAMTS4 was determined in colorectal tumors of different cancer stages and anatomic sites, and in three cell lines of different aggressiveness. Results: The overexpression of ADAMTS4 was observed in tissue samples by IHC, and this was mainly located in the cytoplasm, as detected by FISH. The qRT-PCR and western blot analyses further supported the clinical sample findings. Conclusion: The present data support the notion that the overexpression of ADAMTS4 in CRC might be useful as a non-invasive biomarker for detecting CRC in patients. KEYWORDS: Neoplasms. Neoplasm Metastasis. ADAMTS4 Protein. INTRODUCTION Colorectal cancer (CRC) is common worldwide Disintegrin and metalloproteinase with throm- and remains as the leading cause of cancer-related bospondin motifs 4 (ADAMTS4), which is capable of deaths in Western countries, as well as in the rest of cleaving aggrecan, brevican, neurocan, and versican, the world.1 More than 1.2 million new cases of CRC is an enzyme encoded by the ADAMTS4 gene,3 and occur every year globally.2 Although screening strat- is also encoded as a member of the ADAMTS protein egies have improved and more effective treatments family.
    [Show full text]